Despite scoring a historic FDA approval last year, Adaptimmune Therapeutics is expressing concerns about its own longevity, cutting preclinical programs and evaluating strategic options. | Despite a ...

Now, as a scientist at the University of Pennsylvania, Charly is working to rewrite the future of cancer treatment.

Preclinical pipeline re-prioritization to focus on four potentially transformative programs to advance toward clinic, led by CNTY-308 in B-cell ...

Germinal centers are high-speed evolution machines. Tiny clusters in the lymph nodes, germinal centers refine antibodies through mutation and expansion until they produce high-affinity B cells adapted ...

Fruzaqla given in combination with sintilimab slowed progression in the second line for those with locally advanced or metastatic renal cell carcinoma.

Germinal centers are high-speed evolution machines. Tiny clusters in the lymph nodes, germinal centers refine antibodies ...

"The character of war continues to change," the general said. "The proliferation of technology has made signature management ...

In atopic dermatitis, psoriasis and other dermatologic diseases, T cells lose tolerance to self-antigens, triggering the autoimmune response that leads to abnormal skin cell proliferation and ...

Discover how the ALA-CART platform enhances CAR T cell efficacy against antigen-low leukemias. With improved LAT activation, ...

UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare ...